Sign In to View Organizational & Contract Pricing.
Select a Size
Change View
About This Item
Empirical Formula (Hill Notation):
C24H34O4
CAS Number:
Molecular Weight:
386.52
UNSPSC Code:
41116107
NACRES:
NA.24
PubChem Substance ID:
MDL number:
Beilstein/REAXYS Number:
2066112
grade
pharmaceutical primary standard
API family
medroxyprogesterone
manufacturer/tradename
USP
mp
206-207 °C (lit.)
application(s)
pharmaceutical (small molecule)
format
neat
SMILES string
[H][C@@]12C[C@H](C)C3=CC(=O)CC[C@]3(C)[C@@]1([H])CC[C@@]4(C)[C@@]2([H])CC[C@]4(OC(C)=O)C(C)=O
InChI
1S/C24H34O4/c1-14-12-18-19(22(4)9-6-17(27)13-21(14)22)7-10-23(5)20(18)8-11-24(23,15(2)25)28-16(3)26/h13-14,18-20H,6-12H2,1-5H3/t14-,18+,19-,20-,22+,23-,24-/m0/s1
InChI key
PSGAAPLEWMOORI-PEINSRQWSA-N
Gene Information
human ... PGR(5241)
General description
This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.
Application
Medroxyprogesterone acetate USP reference standard, intended for use in specified quality tests and assays as specified in the USP compendia. Also, for use with USP monographs such as:
- Medroxyprogesterone Acetate Injectable Suspension
- Medroxyprogesterone Acetate Tablets
Analysis Note
These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.
Other Notes
Sales restrictions may apply.
Still not finding the right product?
Explore all of our products under Medroxyprogesterone acetate
signalword
Warning
hcodes
Hazard Classifications
Aquatic Chronic 4 - Carc. 2
Storage Class
11 - Combustible Solids
Regulatory Information
涉药品监管产品
This item has
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Edith R Guilbert et al.
Contraception, 79(3), 167-177 (2009-02-03)
In the fall of 2007, the controversy about the contraceptive use of depot-medroxyprogesterone acetate (DMPA) and its potential impact on skeletal health reached the media in the province of Quebec, Canada, thereby becoming a matter of concern for the lay
Carolyn Westhoff
Contraception, 68(2), 75-87 (2003-09-05)
Depot-medroxyprogesterone acetate (Depo-Provera(R)) is a highly effective, nondaily hormonal contraceptive option that has been available in the United States for a decade, and worldwide for 40 years. Benefits and risks of hormonal therapy are often under scrutiny; however, long-term clinical
J Mitsushita et al.
Gynecologic oncology, 79(1), 129-132 (2000-09-28)
Successful pregnancies after conservative progestin treatment to young women with endometrial carcinoma have recently been reported. However, it is not known for certain whether the lesion is completely eradicated in such patients. We present a case of residual endometrial carcinoma
Global Trade Item Number
| SKU | GTIN |
|---|---|
| 1378001-200MG | 04061838732033 |
